Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 31 / Drugs : 39 - (DrugBank : 15) / Drug target genes : 12 - Drug target pathways : 116

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

ADD-ON sirolimus therapy
   Ruijin Hospital
      2025   -   NCT07151157   China
Aminolevulinic acid
   Kawakami Atsushi
      2023   Phase 2   JPRN-jRCT2071220086   -
      2022   Phase 2   JPRN-jRCT2071220040   -
Anakinra
   Helsinki University
      2005   Phase 2   NCT01033656   Sweden
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
   Ruijin Hospital
      2025   -   NCT07191444   China
   Ruijin Hospital, Shanghai JiaoTong University School of Medicine
      2025   Phase 4   ChiCTR2500109835   China
   Sydvestjysk Sygehus
      2006   Phase 2   EUCTR2005-003173-24-DK   Denmark;Finland;Sweden
   Takeshi KUROSAWA
      2023   Phase 3   JPRN-jRCT2031220222   -
Arava
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
Azathioprin
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
   Sydvestjysk Sygehus
      2006   Phase 2   EUCTR2005-003173-24-DK   Denmark;Finland;Sweden
Baricitinib
   Tianjin Medical University General Hospital
      2020   -   ChiCTR2200061599   China
Camoteskimab
   Apollo Therapeutics Ltd
      2021   Phase 1   NCT04752371   Belgium;Poland;Ukraine;United States
Canakinumab
   Charite University, Berlin, Germany
      2012   Phase 2   NCT02204293   Germany
   Charité - Universitätsmedizin Berlin
      2012   Phase 2   EUCTR2011-001027-20-DE   Germany
   Maruyama Hideki
      2021   Phase 3   JPRN-jRCT2011200022   -
   Novartis Pharmaceuticals
      2021   Phase 3   NCT04717635   Japan
Comparators
   Helsinki University
      2005   Phase 2   NCT01033656   Sweden
Cyclosporin A
   Department of Rheumatology, Renji Hospital South Campus, School of Medicine, Shanghai JiaoTong University
      2017   -   ChiCTR-INR-17013144   China
   Sydvestjysk Sygehus
      2006   Phase 2   EUCTR2005-003173-24-DK   Denmark;Finland;Sweden
Cyklosporin A
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
Deferasirox
   South Hospital of Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
      2020   Phase 0   ChiCTR2000034186   China
Emapalumab
   Ochiai Kazuya
      2023   Phase 2-3   JPRN-jRCT2031220187   Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Swedish Orphan Biovitrum
      2018   Phase 2   NCT03311854   France;Italy;Netherlands;Spain;United Kingdom;United States
   Swedish Orphan Biovitrum AG
      2017   Phase 2   EUCTR2016-004223-23-GB   Canada;France;Italy;Netherlands;Spain;United Kingdom;United States
Etoposide
   Department of Rheumatology, Renji Hospital South Campus, School of Medicine, Shanghai JiaoTong University
      2017   -   ChiCTR-INR-17013144   China
EU/1/09/564/004
   Charité - Universitätsmedizin Berlin
      2012   Phase 2   EUCTR2011-001027-20-DE   Germany
Examination
   Yokohama City University Graduate School of Medicine, Department of Internal Medicine and Clinical Immunology
      2013   -   JPRN-UMIN000012379   Japan
Firsekibart
   Ruijin Hospital
      2025   -   NCT07191444   China
   Ruijin Hospital, Shanghai JiaoTong University School of Medicine
      2025   Phase 4   ChiCTR2500109835   China
GNR-086
   AO GENERIUM
      2023   Phase 3   NCT06497491   Russia
Ilaris
   AO GENERIUM
      2023   Phase 3   NCT06497491   Russia
   Charité - Universitätsmedizin Berlin
      2012   Phase 2   EUCTR2011-001027-20-DE   Germany
Imurel
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
Kineret 100 MG injection
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
Kineret injection
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
   Sydvestjysk Sygehus
      2006   Phase 2   EUCTR2005-003173-24-DK   Denmark;Finland;Sweden
Leflunomide
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
   Sydvestjysk Sygehus
      2006   Phase 2   EUCTR2005-003173-24-DK   Denmark;Finland;Sweden
Methotrexate
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
   Sydvestjysk Sygehus
      2006   Phase 2   EUCTR2005-003173-24-DK   Denmark;Finland;Sweden
NI-0501
   Swedish Orphan Biovitrum AG
      2017   Phase 2   EUCTR2016-004223-23-GB   Canada;France;Italy;Netherlands;Spain;United Kingdom;United States
Prednisolone
   Kawakami Atsushi
      2020   -   JPRN-jRCTs071190042   -
RPH-104
   R-Pharm International, LLC
      2023   Phase 3   NCT05432960   Russian Federation
Salazopyrin EN
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
Sandimmun neoral
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
Sulfasalazin
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
   Sydvestjysk Sygehus
      2006   Phase 2   EUCTR2005-003173-24-DK   Denmark;Finland;Sweden
Tadekinig alfa
   AB2 Bio Ltd.
      2015   Phase 2   NCT02398435   France;Germany;Switzerland
Tocilizumab
   Department of Rheumatology & Clinical Immunology,Saitama Medical Center, Saitama Medical Universitity
      2012   -   JPRN-UMIN000007019   Japan
   Division of Rheumatology & Clinical Immunology, Jichi Medical University
      2008   -   JPRN-UMIN000001457   Japan
      2008   -   JPRN-UMIN000001250   Japan